Neuzulassung bei Nierenzellkarzinom: Cabozantinib für die Second-Line-Therapie
Crossref DOI link: https://doi.org/10.1007/s00092-016-1280-x
Published Online: 2016-11-05
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Meißner, Thomas
